{"type": "dataset", "dataset_id": "db7592d0-6206-5684-a29c-8059a6033241", "dataset_version": "0.1.0", "children": [{"type": "file", "dataset_id": "db7592d0-6206-5684-a29c-8059a6033241", "dataset_version": "0.1.0", "metadata_sources": {"key_source_map": {}, "sources": [{"source_name": "tabby", "source_version": "0.1.0", "source_parameter": {}, "source_time": 1708434643.468162, "agent_name": "Tosca Heunis", "agent_email": "t.heunis@fz-juelich.de"}]}, "path": "cPIRA_OCR_ps_220918_w_CD19.xlsx", "contentbytesize": 62318, "name": "cPIRA_OCR_ps_220918_w_CD19.xlsx"}], "metadata_sources": {"key_source_map": {"name": ["tabby"], "description": ["tabby"], "authors": ["tabby"], "keywords": ["tabby"], "publications": ["tabby"], "access_request_contact": ["tabby"], "additional_display": ["tabby"]}, "sources": [{"source_name": "tabby", "source_version": "0.1.0", "source_parameter": {}, "source_time": 1708434643.360662, "agent_name": "Tosca Heunis", "agent_email": "t.heunis@fz-juelich.de"}]}, "name": "Longitudinal clinical data in Ocrelizumab-treated multiple sclerosis patients", "description": "A clinical dataset of ocrelizumab treated multiple sclerosis patients at the HHU University Clinic D\u00fcsseldorf with routinely collected clinical, imaging and OCT results (no imaging data). Data was collected for routine visits from 2018 to 2022. ", "authors": [{"name": "Jens Ingwersen"}, {"name": "Lars Masanneck", "identifiers": [{"name": "ORCID", "identifier": "0000-0003-2496-1415"}]}, {"name": "Marc Pawlitzki"}, {"name": "Sara Samadzadeh"}, {"name": "Margit Weise"}, {"name": "Orhan Aktas"}, {"name": "Sven G. Meuth"}, {"name": "Philipp Albrecht"}], "keywords": ["clinical data", "multiple sclerosis", "ocrelizumab", "PIRA", "EDSS"], "publications": [{"@type": "schema:CreativeWork", "datePublished": "2023-09-11", "doi": "https://doi.org/10.1038/s41598-023-40940-w", "schema:url": "https://www.nature.com/articles/s41598-023-40940-w", "title": "Ingwersen, J., Masanneck, L., Pawlitzki, M. et al. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci Rep 13, 15003 (2023).", "authors": []}], "access_request_contact": {"givenName": "Lars", "familyName": "Masanneck", "email": "lars.masanneck@med.uni-duesseldorf.de"}, "additional_display": [{"name": "ABCD-J", "icon": "fa-solid fa-graduation-cap", "content": {"@context": {"homepage": "https://schema.org/mainEntityOfPage", "data controller": "https://w3id.org/dpv#hasDataController", "sample (organism)": "https://openminds.ebrains.eu/controlledTerms/Species", "sample (organism part)": "https://openminds.ebrains.eu/controlledTerms/UBERONParcellation", "used for": "http://www.w3.org/ns/prov#hadUsage"}, "sample (organism)": {"@type": "https://openminds.ebrains.eu/controlledTerms/Species", "name": "Homo sapiens", "preferredOntologyIdentifier": "http://purl.obolibrary.org/obo/NCBITaxon_9606", "synonym": "human"}, "sample (organism part)": {"@type": "https://openminds.ebrains.eu/controlledTerms/UBERONParcellation", "name": "brain", "preferredOntologyIdentifier": "http://purl.obolibrary.org/obo/UBERON_0000955"}, "data controller": {"@type": "https://schema.org/Person", "address": "Geb. 13.53, Moorenstra\u00dfe 5, 40225 D\u00fcsseldorf", "email": "lars.masanneck@med.uni-duesseldorf.de", "name": "Lars Masanneck"}, "used for": {"@type": "https://schema.org/Thing", "name": "Progression independent from relapse in ocrelizumab-treated relapsing multiple sclerosis cohort"}}}]}